The Role of New Technologies in Myeloproliferative Neoplasms
Conclusions The discovery of JAK2V617F mutation in BCR-ABL1-negative MPNs by four different international cooperative groups in 2005 (2–5) led to significant insights on the pathogenesis of these disorders. In fact, this mutation results in a gain-of-function with activation of cytokine and growth factor receptors, and thus of the downstream JAK-STAT pathway (79, 95–98). The JAK2 point mutation in exon 12, present in a small percentage of patients with PV, is able to induce the MPN phenotype through the same pathogenic mechanism (6, 7). In 2006 the MPLW515L/K was reported in ET and PMF patients (44, 45) and demonstrated to be able to aberrantly activate JAK-STAT pathway through a gain-of function similar to that of JAK2, thus leading to megakaryocytic proliferation (8–10). More recently, in 2013 two different groups demonstrated a spectrum of mutations in CALR gene that cause frameshifts of one base pair in the last coding exon with a generation of a protein with new C terminus and a tail of 36 aminoacids (11, 12). Although it was soon clear that JAK-STAT signaling pathway was consistently activated in CALR mutated cells (53, 99), only recently it has been demonstrated that the mutant CALR protein is able to bind to the MPL receptor and activate it independently of the TPO presence itself (54–57). Consistently with the fact that all these mutations cause JAK-STAT pathway activation, ruxolitinib, the first JAK1/2 inhibitor, is able to exert clinical ...
Authors: Kabeya T, Mima S, Imakura Y, Miyashita T, Ogura I, Yamada T, Yasujima T, Yuasa H, Iwao T, Matsunaga T Abstract To develop a novel intestinal drug absorption system using intestinal epithelial cells derived from human induced pluripotent stem (iPS) cells, the cells must possess sufficient pharmacokinetic functions. However, the CYP3A4/5 activities of human iPS cell-derived small intestinal epithelial cells prepared using conventional differentiation methods is low. Further, studies of the CYP3A4/5 activities of human iPS-derived and primary small intestinal cells are not available. To fill this gap in our k...
Publication date: Available online 11 July 2020Source: Journal of Trace Elements in Medicine and BiologyAuthor(s): Wojciech Żwierełło, Daniel Styburski, Agnieszka Maruszewska, Krzysztof Piorun, Marta Skórka-Majewicz, Maja Czerwińska, Dominika Maciejewska, Irena Baranowska-Bosiacka, Andrzej Krajewski, Izabela Gutowska
Publication date: Available online 12 July 2020Source: Biochimica et Biophysica Acta (BBA) - General SubjectsAuthor(s): Sumit Sahni, Christoph Krisp, Mark P. Molloy, Christopher Nahm, Sarah Maloney, Josef Gillson, Anthony J. Gill, Jaswinder Samra, Anubhav Mittal
Analyst, 2020, Accepted Manuscript DOI: 10.1039/D0AN01011A, PaperXiaonan Gao, Congcong Zhao, Keyan Wei, Bo Hu, Yu-Qin Chen, Kehua Xu, Bo Tang The anticancer mechanism for reduced/oxidized ascorbic acid (AA/DHA) is of great significance for clinical cancer therapies. A pH controlled fluorescent nanocarrier was designed to targetable deliver AA and DHA into... The content of this RSS Feed (c) The Royal Society of Chemistry
Cancer therapies could potentially be more effective if their development took into account the cells that give rise to tumor-fighting cells.
A study suggests the potential for a noninvasive diagnostic that could detect tumors early and differentiate between disease types.
Better understanding the CD8+ T cells already present in tumors could be key to making immunotherapies work for more patients.
CONCLUSION: The results of this study show that the four groups created from the two questions render it possible to distinguish persons in terms of indicators measuring the mental and general health of the Quebec population. Convergence of results in all three cycles lends additional credence to the use of questions on received diagnoses of mood and anxiety disorders. PMID: 32651010 [PubMed - as supplied by publisher]
Publication date: Available online 12 July 2020Source: Journal of the American College of RadiologyAuthor(s): Lori A. Deitte, Tara M. Catanzano, Christopher P. Ho, Madelene C. Lewis
I have a late 30's female patient with a history of leukemia (bone marrow transplant, chemo, nephrectomy), who has lateral hip and thigh pain. Unilateral pain. No obvious exacerbating or alleviating factors. Moderate to severe intensity, constant. She's got femoral diaphysis infarctions, several of them, and they match up exactly where she hurts. The lateral hip distribution isn't the main focus, it is the proximal and lateral thigh. She's got buttock pain as well, which was positive on... Bone pain?
More News: Academia | Acute Leukemia | Acute Lymphoblastic Leukemia | Acute Myeloid Leukemia | Biology | Bone Marrow Transplant | Burns | Calcium | Canada Health | Cancer | Cancer & Oncology | Cancer in Adolescents | Cancer in Young Adults | Chemistry | Chronic Leukemia | Chronic Myeloid Leukaemia | Chronic Myeloproliferative Neoplasm | Clinical Trials | Genetics | Hematology | International Medicine & Public Health | Italy Health | Laboratory Medicine | Leukemia | Lymphoma | Molecular Biology | Myelodysplastic Syndrome | Myeloproliferative Disorders | Pathology | Physiology | Raynaud's Phenomenom | Reproduction Medicine | Stem Cell Therapy | Stem Cells | Study | Thrombosis | Toxicology | Transplants | UK Health | USA Health | WHO